130 related articles for article (PubMed ID: 31740052)
1. Novel N-acetyl-Glycol-split heparin biotin-conjugates endowed with anti-heparanase activity.
Esposito E; Vlodavsky I; Barash U; Roscilli G; Milazzo FM; Giannini G; Naggi A
Eur J Med Chem; 2020 Jan; 186():111831. PubMed ID: 31740052
[TBL] [Abstract][Full Text] [Related]
2. Modulation of the heparanase-inhibiting activity of heparin through selective desulfation, graded N-acetylation, and glycol splitting.
Naggi A; Casu B; Perez M; Torri G; Cassinelli G; Penco S; Pisano C; Giannini G; Ishai-Michaeli R; Vlodavsky I
J Biol Chem; 2005 Apr; 280(13):12103-13. PubMed ID: 15647251
[TBL] [Abstract][Full Text] [Related]
3. Targeting heparanase overcomes chemoresistance and diminishes relapse in myeloma.
Ramani VC; Zhan F; He J; Barbieri P; Noseda A; Tricot G; Sanderson RD
Oncotarget; 2016 Jan; 7(2):1598-607. PubMed ID: 26624982
[TBL] [Abstract][Full Text] [Related]
4. Arylamidonaphtalene sulfonate compounds as a novel class of heparanase inhibitors.
Rondanin R; Fochi S; Baruchello R; Bernardi T; Oliva P; Semeraro F; Simoni D; Giannini G
Bioorg Med Chem Lett; 2017 Sep; 27(18):4421-4425. PubMed ID: 28811133
[TBL] [Abstract][Full Text] [Related]
5. Investigating Glycol-Split-Heparin-Derived Inhibitors of Heparanase: A Study of Synthetic Trisaccharides.
Ni M; Elli S; Naggi A; Guerrini M; Torri G; Petitou M
Molecules; 2016 Nov; 21(11):. PubMed ID: 27886097
[TBL] [Abstract][Full Text] [Related]
6. Chemical modifications of heparin that diminish its anticoagulant but preserve its heparanase-inhibitory, angiostatic, anti-tumor and anti-metastatic properties.
Lapierre F; Holme K; Lam L; Tressler RJ; Storm N; Wee J; Stack RJ; Castellot J; Tyrrell DJ
Glycobiology; 1996 Apr; 6(3):355-66. PubMed ID: 8724143
[TBL] [Abstract][Full Text] [Related]
7. Structural requirements for inhibition of melanoma lung colonization by heparanase inhibiting species of heparin.
Bitan M; Mohsen M; Levi E; Wygoda MR; Miao HQ; Lider O; Svahn CM; Ekre HP; Ishai-Michaeli R; Bar-Shavit R
Isr J Med Sci; 1995; 31(2-3):106-18. PubMed ID: 7744578
[TBL] [Abstract][Full Text] [Related]
8. Kinetic analysis and molecular modeling of the inhibition mechanism of roneparstat (SST0001) on human heparanase.
Pala D; Rivara S; Mor M; Milazzo FM; Roscilli G; Pavoni E; Giannini G
Glycobiology; 2016 Jun; 26(6):640-54. PubMed ID: 26762172
[TBL] [Abstract][Full Text] [Related]
9. Chemically modified heparins as inhibitors of heparan sulfate specific endo-beta-glucuronidase (heparanase) of metastatic melanoma cells.
Irimura T; Nakajima M; Nicolson GL
Biochemistry; 1986 Sep; 25(18):5322-8. PubMed ID: 3768351
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of tumor metastasis by heparanase inhibiting species of heparin.
Vlodavsky I; Mohsen M; Lider O; Svahn CM; Ekre HP; Vigoda M; Ishai-Michaeli R; Peretz T
Invasion Metastasis; 1994-1995; 14(1-6):290-302. PubMed ID: 7657522
[TBL] [Abstract][Full Text] [Related]
11. Roneparstat: Development, Preclinical and Clinical Studies.
Noseda A; Barbieri P
Adv Exp Med Biol; 2020; 1221():523-538. PubMed ID: 32274725
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of heparanase activity and tumor metastasis by laminarin sulfate and synthetic phosphorothioate oligodeoxynucleotides.
Miao HQ; Elkin M; Aingorn E; Ishai-Michaeli R; Stein CA; Vlodavsky I
Int J Cancer; 1999 Oct; 83(3):424-31. PubMed ID: 10495437
[TBL] [Abstract][Full Text] [Related]
13. Structural features of heparanase-inhibiting non-anticoagulant heparin derivative Roneparstat.
Alekseeva A; Mazzini G; Giannini G; Naggi A
Carbohydr Polym; 2017 Jan; 156():470-480. PubMed ID: 27842848
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of B16-BL6 melanoma lung colonies by semisynthetic sulfaminoheparosan sulfates from E. coli K5 polysaccharide.
Poggi A; Rossi C; Casella N; Bruno C; Sturiale L; Dossi C; Naggi A
Semin Thromb Hemost; 2002 Aug; 28(4):383-92. PubMed ID: 12244486
[TBL] [Abstract][Full Text] [Related]
15. Non-Anticoagulant Heparins as Heparanase Inhibitors.
Cassinelli G; Torri G; Naggi A
Adv Exp Med Biol; 2020; 1221():493-522. PubMed ID: 32274724
[TBL] [Abstract][Full Text] [Related]
16. Heparanase gene silencing, tumor invasiveness, angiogenesis, and metastasis.
Edovitsky E; Elkin M; Zcharia E; Peretz T; Vlodavsky I
J Natl Cancer Inst; 2004 Aug; 96(16):1219-30. PubMed ID: 15316057
[TBL] [Abstract][Full Text] [Related]
17. Heparanase: From basic research to therapeutic applications in cancer and inflammation.
Vlodavsky I; Singh P; Boyango I; Gutter-Kapon L; Elkin M; Sanderson RD; Ilan N
Drug Resist Updat; 2016 Nov; 29():54-75. PubMed ID: 27912844
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and in vitro α-glucosidase inhibition of novel dihydropyrano[3,2-c]quinoline derivatives as potential anti-diabetic agents.
Nikookar H; Mohammadi-Khanaposhtani M; Imanparast S; Faramarzi MA; Ranjbar PR; Mahdavi M; Larijani B
Bioorg Chem; 2018 Apr; 77():280-286. PubMed ID: 29421703
[TBL] [Abstract][Full Text] [Related]
19. 1-[4-(1H-Benzoimidazol-2-yl)-phenyl]-3-[4-(1H-benzoimidazol-2-yl)-phenyl]-urea derivatives as small molecule heparanase inhibitors.
Pan W; Miao HQ; Xu YJ; Navarro EC; Tonra JR; Corcoran E; Lahiji A; Kussie P; Kiselyov AS; Wong WC; Liu H
Bioorg Med Chem Lett; 2006 Jan; 16(2):409-12. PubMed ID: 16246560
[TBL] [Abstract][Full Text] [Related]
20. Production of heparin and λ-carrageenan anti-heparanase derivatives using a combination of physicochemical depolymerization and glycol splitting.
Poupard N; Groult H; Bodin J; Bridiau N; Bordenave-Juchereau S; Sannier F; Piot JM; Fruitier-Arnaudin I; Maugard T
Carbohydr Polym; 2017 Jun; 166():156-165. PubMed ID: 28385219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]